Literature DB >> 32389792

Characterization of fosfomycin heteroresistance among multidrug-resistant Escherichia coli isolates from hospitalized patients in Rio de Janeiro, Brazil.

Ana Carolina da C Campos1, Nathália L Andrade2, Natacha Couto3, Nico T Mutters4, Marjon de Vos5, Ana Cláudia de P Rosa2, Paulo V Damasco6, Jerome R Lo Ten Foe3, Alex W Friedrich3, Monika A Chlebowicz-Flissikowska3, John W A Rossen7.   

Abstract

OBJECTIVES: Urinary tract infections (UTIs) caused by multidrug-resistant Escherichia coli have become a major medical concern. Old antibiotics such as fosfomycin have become an alternative therapeutic option due to their effectiveness and, as a result, fosfomycin is now used as a first-line drug for the treatment of UTIs in many countries. Despite low resistance rates, fosfomycin heteroresistance, defined as a phenomenon where subpopulations of bacteria are resistant to high antibiotic concentrations whereas most of the bacteria are susceptible, is an underestimated problem.
METHODS: The frequency of heteroresistance in E. coli isolated from hospitalized patients in Brazil and its effect on susceptibility of E. coli in biofilms was studied and the isolates were molecularly characterized to reveal the mechanisms behind their fosfomycin heteroresistance using whole-genome sequencing.
RESULTS: A higher frequency of fosfomycin heteroresistance compared with other studies was found. In biofilms, most heteroresistant isolates were less sensitive to fosfomycin than control isolates and showed overexpression of metabolic genes thereby increasing their survival rate. Molecular characterization showed that some resistant subpopulations derived from heteroresistant isolates had a defect in their fosfomycin uptake system caused by mutations in transporter and regulatory genes, whereas others overexpressed the murA gene. None to minor effects on bacterial fitness were observed. Oxidative stress protection, virulence and metabolic genes were differentially expressed in resistant subpopulations and heteroresistant isolates.
CONCLUSION: Frequent detection of heteroresistance in UTIs may play a role in the failure of antibiotic treatments and should therefore be more carefully diagnosed.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Escherichia coli; Fosfomycin; Heteroresistance; Next-generation sequencing; Urinary tract infection; murA

Mesh:

Substances:

Year:  2020        PMID: 32389792     DOI: 10.1016/j.jgar.2020.04.026

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  2 in total

1.  High-Frequency Detection of fosA3 and bla CTX-M-55 Genes in Escherichia coli From Longitudinal Monitoring in Broiler Chicken Farms.

Authors:  Maísa Fabiana Menck-Costa; Ana Angelita Sampaio Baptista; Luiz Eduardo de Souza Gazal; Larissa Justino; Matheus Silva Sanches; Marielen de Souza; Erick Kenji Nishio; Beatriz Queiroz Dos Santos; Victor Dellevedove Cruz; João Vitor Monteiro Berbert; Bruna Carolina Gonçalves; Galdino Andrade; Eliana Carolina Vespero; Gerson Nakazato; Renata Katsuko Takayama Kobayashi
Journal:  Front Microbiol       Date:  2022-05-18       Impact factor: 6.064

2.  Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS).

Authors:  Kathryn M Thomson; Calie Dyer; Feiyan Liu; Kirsty Sands; Edward Portal; Maria J Carvalho; Matthew Barrell; Ian Boostrom; Susanna Dunachie; Refath Farzana; Ana Ferreira; Francis Frayne; Brekhna Hassan; Ellis Jones; Lim Jones; Jordan Mathias; Rebecca Milton; Jessica Rees; Grace J Chan; Delayehu Bekele; Abayneh Mahlet; Sulagna Basu; Ranjan K Nandy; Bijan Saha; Kenneth Iregbu; Fatima Modibbo; Stella Uwaezuoke; Rabaab Zahra; Haider Shirazi; Najeeb U Syed; Jean-Baptiste Mazarati; Aniceth Rucogoza; Lucie Gaju; Shaheen Mehtar; Andre N H Bulabula; Andrew Whitelaw; Johan G C van Hasselt; Timothy R Walsh
Journal:  Lancet Infect Dis       Date:  2021-08-09       Impact factor: 25.071

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.